News

November 26, 2019

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.


Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

September 5, 2018

Proceeds to accelerate expansion of global clinical research program and establish new production facilities to meet growing demand for the company's breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).

TEL AVIV, Israel, -- Alpha Tau M...

August 22, 2018

Alpha Tau is in the last stages of raising an investment of several tens of millions of dollars.

Israeli oncology company Alpha Tau Medical Ltd. is in the last stages of raising an investment of several tens of millions of dollars, one person familiar with the matter to...

August 22, 2018

The new Sealed Source and Device (SSD) approval enables the commencement of clinical trials in leading hospitals across the U.S. with the company’s breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).  

Boston, MA, August 21st 2018 --...

July 15, 2018

Alpha Tau Medical focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid tumors. Alpha DaRT, initially developed at Tel Aviv University, was shown to be effective and safe for treatin...

Please reload

Categories
Please reload

Sign up
Featured Posts

Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

April 11, 2019

1/5
Please reload

Archive
Please reload

Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

CONTACT US

Are you looking to participate in clinical trials?

Take our self-assessment test to find potentially suitable studies.

For other inquiries, please visit our contact page.